<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998425</url>
  </required_header>
  <id_info>
    <org_study_id>IRB100-2929B-FibLC-CGMH</org_study_id>
    <nct_id>NCT01998425</nct_id>
  </id_info>
  <brief_title>Circulating Fibrocytes in Non-small Cell Lung Cancer.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will collect fibrocytes (CD45+Col-1+) in patients with non-small cell lung
      cancer (NSCLC). The investigators hypothesize that patients with NSCLC experience expansion
      of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating
      immune escape in NSCLC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibrocytes have been described in both mice and humans, where they bear a hematopoietic
      progenitor phenotype (CD45+Col-1+). Fibrocytes have previously been described in murine
      cancer, implicated as mediators of tumor immune escape. In this study, the investigators will
      collect fibrocytes including CD45+Col-1+ expression. The cells express indoleamine oxidase,
      which is primarily responsible for their immunosuppressive properties. The investigators
      hypothesize that patients with non-small cell lung cancer experience expansion of
      immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune
      escape in non-small cell lung cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>treatment response of participants by RECIST.</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation of circulating fibrocytes and treatment (chemotherapy, surgery, target treatment) response of patients with NSCLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival of participants.</measure>
    <time_frame>24 months</time_frame>
    <description>Correlation of circulating fibrocytes and survival (progression free survival, disease free survival and overall survival) of patients with NSCLC.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Staging status of patients with NSCLC.</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation of circulating fibrocytes and stage of patients with NSCLC.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Non-small cell lung cancer</arm_group_label>
    <description>The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
        will be enrolled and evaluated from 2013 to 2016. Disease in all cases was staged with
        computed tomography (CT) of the chest, breast (if resectable) and positron emission
        tomography (PET, if resectable) within 3 months before enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

        Exclusion Criteria:

          -  Combination of other malignancy.

          -  Age less than 20 years (not include 20 years).

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fu-Tsai Chung</last_name>
    <email>vikingchung@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fu-Tsai Chung</last_name>
      <email>vikingchung@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Fu-Tsai Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Han-Pin Kuo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Hua Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yueh-Fu Fang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting-Yu Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Teng Yu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memoral Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fu-Tsai Chung</last_name>
      <email>vikingchung@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Fu-Tsai Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meng-Heng Hsieh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Horng-Chyuan Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Hsi Kuo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Weng CM, Chen BC, Wang CH, Feng PH, Lee MJ, Huang CD, Kuo HP, Lin CH. The endothelin A receptor mediates fibrocyte differentiation in chronic obstructive asthma. The involvement of connective tissue growth factor. Am J Respir Crit Care Med. 2013 Aug 1;188(3):298-308. doi: 10.1164/rccm.201301-0132OC.</citation>
    <PMID>23795584</PMID>
  </reference>
  <reference>
    <citation>Wang CH, Huang CD, Lin HC, Huang TT, Lee KY, Lo YL, Lin SM, Chung KF, Kuo HP. Increased activation of fibrocytes in patients with chronic obstructive asthma through an epidermal growth factor receptor-dependent pathway. J Allergy Clin Immunol. 2012 May;129(5):1367-76. doi: 10.1016/j.jaci.2012.01.038. Epub 2012 Feb 9.</citation>
    <PMID>22325070</PMID>
  </reference>
  <reference>
    <citation>Wang CH, Huang CD, Lin HC, Lee KY, Lin SM, Liu CY, Huang KH, Ko YS, Chung KF, Kuo HP. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care Med. 2008 Sep 15;178(6):583-91. doi: 10.1164/rccm.200710-1557OC. Epub 2008 Jun 26.</citation>
    <PMID>18583572</PMID>
  </reference>
  <reference>
    <citation>Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, Chou CL, Chen HC, Lin SM, Kuo HP. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer. 2012 Aug 1;131(3):E227-35. doi: 10.1002/ijc.27403. Epub 2012 Jan 11.</citation>
    <PMID>22174092</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, Mackall CL. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 2013 Aug 15;122(7):1105-13. doi: 10.1182/blood-2012-08-449413. Epub 2013 Jun 11.</citation>
    <PMID>23757729</PMID>
  </reference>
  <reference>
    <citation>Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, Lin TY, Chung FT, Kuo CS, Yu CT, Lin SM, Wang CH, Chou CL, Huang CD, Kuo HP. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med. 2012 Nov 15;186(10):1025-36. doi: 10.1164/rccm.201204-0636OC. Epub 2012 Sep 6.</citation>
    <PMID>22955317</PMID>
  </reference>
  <reference>
    <citation>Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14‚Åª/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45. doi: 10.1007/s00432-009-0634-0.</citation>
    <PMID>19572148</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>circulating fibrocytes</keyword>
  <keyword>fibrocyte</keyword>
  <keyword>NSCLC</keyword>
  <keyword>treatment response</keyword>
  <keyword>survival</keyword>
  <keyword>stage</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

